IDEA4RC FHIR Implementation Guide
0.1.0 - CI Build
150
IDEA4RC FHIR Implementation Guide
0.1.0 - CI Build
150
IDEA4RC FHIR Implementation Guide, published by IDEA4RC Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/idea4rc/ and changes regularly. See the Directory of published versions
| Official URL: http://hl7.eu/fhir/ig/idea4rc/ValueSet/drugsAtc-eu-i4rc | Version: 0.1.0 | |||
| Draft as of 2026-01-19 | Computable Name: VsI4rcAtcCodes | |||
List of WHO ATC codes for antineoplastic and immunostimulating agents.
References
This value set is not used here; it may be used elsewhere (e.g. specifications and/or implementations that use this content)
http://www.whocc.no/atc version Not Stated (use latest from terminology server)| Code | Display |
| L01AA01 | Cyclophosphamide |
| L01AA02 | Chlorambucil |
| L01AA03 | Melphalan |
| L01AA05 | Chlormethine |
| L01AA06 | Ifosfamide |
| L01AA07 | Trofosfamide |
| L01AA08 | Prednimustine |
| L01AA09 | Bendamustine |
| L01AB01 | Busulfan |
| L01AB02 | Treosulfan |
| L01AB03 | Mannosulfan |
| L01AC01 | Thiotepa |
| L01AC02 | Triaziquone |
| L01AC03 | Carboquone |
| L01AD01 | Carmustine |
| L01AD02 | Lomustine |
| L01AD03 | Semustine |
| L01AD04 | Streptozocin |
| L01AD05 | Fotemustine |
| L01AD06 | Nimustine |
| L01AD07 | Ranimustine |
| L01AG01 | Etoglucid |
| L01AX | Peptichemio |
| L01AX01 | Mitobronitol |
| L01AX02 | Pipobroman |
| L01AX03 | Temozolomide |
| L01AX04 | Dacarbazine |
| L01BA01 | Methotrexate |
| L01BA03 | Raltitrexed |
| L01BA04 | Pemetrexed |
| L01BA05 | Pralatrexate |
| L01BB02 | Mercaptopurine |
| L01BB03 | Thioguanine |
| L01BB04 | Cladribine |
| L01BB05 | Fludarabine |
| L01BB06 | Clofarabine |
| L01BB07 | Nelarabine |
| L01BC01 | Cytarabine |
| L01BC02 | Fluorouracil |
| L01BC03 | Tegafur |
| L01BC04 | Carmofur |
| L01BC05 | Gemcitabine |
| L01BC06 | Capecitabine |
| L01BC07 | Azacitidine |
| L01BC08 | Decitabine |
| L01BC52 | Fluorouracil, combinations |
| L01BC53 | Tegafur, combinations |
| L01BC59 | Trifluridine, combinations |
| L01CA01 | Vinblastine |
| L01CA02 | Vincristine |
| L01CA03 | Vindesine |
| L01CA04 | Vinorelbine |
| L01CA05 | Vinflunine |
| L01CA06 | Vintafolide |
| L01CB01 | Etoposide |
| L01CB02 | Teniposide |
| L01CC01 | Demecolcine |
| L01CD01 | Paclitaxel |
| L01CD02 | Docetaxel |
| L01CD03 | Paclitaxel poliglumex |
| L01CD04 | Cabazitaxel |
| L01CX01 | Trabectedin |
| L01DA01 | Dactinomycin |
| L01DB01 | Doxorubicin |
| L01DB02 | Daunorubicin |
| L01DB03 | Epirubicin |
| L01DB04 | Aclarubicin |
| L01DB05 | Zorubicin |
| L01DB06 | Idarubicin |
| L01DB07 | Mitoxantrone |
| L01DB08 | Pirarubicin |
| L01DB09 | Valrubicin |
| L01DB10 | Amrubicin |
| L01DB11 | Pixantrone |
| L01DC01 | Bleomycin |
| L01DC02 | Mithramycin |
| L01DC03 | Mitomycin |
| L01DC04 | Ixabepilone |
| L01XA01 | Cisplatin |
| L01XA02 | Carboplatin |
| L01XA03 | Oxaliplatin |
| L01XA04 | Satraplatin |
| L01XA05 | Polyplatillen |
| L01XB01 | Procarbazine |
| L01XC01 | Edrecolomab |
| L01XC02 | Rituximab |
| L01XC03 | Trastuzumab |
| L01XC04 | Alemtuzumab |
| L01XC05 | Gemtuzumab |
| L01XC06 | Cetuximab |
| L01XC07 | Bevacizumab |
| L01XC08 | Panitumumab |
| L01XC09 | Catumaxomab |
| L01XC10 | Ofatumumab |
| L01XC11 | Ipilimumab |
| L01XC12 | Brentuximab vedotin |
| L01XC13 | Pertuzumab |
| L01XC14 | Trastuzumab emtansine |
| L01XC15 | Obinutuzumab |
| L01XC16 | Dinutuximab |
| L01XC17 | Nivolumab |
| L01XC18 | Pembrolizumab |
| L01XC19 | Blinatumomab |
| L01XC21 | Ramucirumab |
| L01XC22 | Necitumumab |
| L01XC23 | Elotuzumab |
| L01XC24 | Daratumumab |
| L01XC25 | Mogamulizumab |
| L01XC26 | Inotuzumab ozogamicin |
| L01XC27 | Olaratumab |
| L01XD01 | Porfimer sodium |
| L01XD03 | Methyl aminolevulinate |
| L01XD04 | Aminolevulinic acid |
| L01XD05 | Temoporfin |
| L01XD06 | Efaproxiral |
| L01XE01 | Imatinib |
| L01XE02 | Gefitinib |
| L01XE03 | Erlotinib |
| L01XE04 | Sunitinib |
| L01XE05 | Sorafenib |
| L01XE06 | Dasatinib |
| L01XE07 | Lapatinib |
| L01XE08 | Nilotinib |
| L01XE09 | Temsirolimus |
| L01XE10 | Everolimus |
| L01XE11 | Pazopanib |
| L01XE12 | Vandetanib |
| L01XE13 | Afatinib |
| L01XE14 | Bosutinib |
| L01XE15 | Vemurafenib |
| L01XE16 | Crizotinib |
| L01XE17 | Axitinib |
| L01XE18 | Ruxolitinib |
| L01XE19 | Ridaforolimus |
| L01XE21 | Regorafenib |
| L01XE22 | Masitinib |
| L01XE23 | Dabrafenib |
| L01XE24 | Ponatinib |
| L01XE25 | Trametinib |
| L01XE26 | Cabozantinib |
| L01XE27 | Ibrutinib |
| L01XE28 | Ceritinib |
| L01XE29 | Lenvatinib |
| L01XE31 | Nintedanib |
| L01XE32 | Cediranib |
| L01XE33 | Palbociclib |
| L01XE34 | Tivozanib |
| L01XE35 | Osimertinib |
| L01XE36 | Alectinib |
| L01XE37 | Rociletinib |
| L01XE38 | Cobimetinib |
| L01XE39 | Midostaurin |
| L01XE40 | Olmutinib |
| L01XX | Other antineoplastic agent |
| L01XX01 | Amsacrine |
| L01XX02 | Asparaginase |
| L01XX03 | Altretamine |
| L01XX05 | Hydroxycarbamide |
| L01XX07 | Lonidamine |
| L01XX08 | Pentostatin |
| L01XX09 | Miltefosine |
| L01XX10 | Masoprocol |
| L01XX11 | Estramustine |
| L01XX14 | Tretinoin |
| L01XX16 | Mitoguazone |
| L01XX17 | Topotecan |
| L01XX18 | Tiazofurine |
| L01XX19 | Irinotecan |
| L01XX22 | Alitretinoin |
| L01XX23 | Mitotane |
| L01XX24 | Pegaspargase |
| L01XX25 | Bexarotene |
| L01XX27 | Arsenic trioxide |
| L01XX29 | Denileukin diftitox |
| L01XX32 | Bortezomib |
| L01XX33 | Celecoxib |
| L01XX35 | Anagrelide |
| L01XX36 | Oblimersen |
| L01XX37 | Sitimagene ceradenovec |
| L01XX38 | Vorinostat |
| L01XX39 | Romidepsin |
| L01XX40 | Omacetaxine mepesuccinate |
| L01XX41 | Eribulin |
| L01XX42 | Panobinostat |
| L01XX43 | Vismodegib |
| L01XX44 | Aflibercept |
| L01XX45 | Carfilzomib |
| L01XX46 | Olaparib |
| L01XX47 | Idelalisib |
| L01XX48 | Sonidegib |
| L01XX49 | Belinostat |
| L01XX50 | Ixazomib |
| L01XX51 | Talimogene laherparepvec |
| L01XX52 | Venetoclax |
| L01XX53 | Vosaroxin |
| L01XY | Combination of antineoplastic agents |
| L02AA01 | Diethylstilbestrol |
| L02AA02 | Polyestradiol phosphate |
| L02AA03 | Ethinylestradiol |
| L02AA04 | Fosfestrol |
| L02AB01 | Megestrol |
| L02AB02 | Medroxyprogesterone |
| L02AB03 | Gestonorone |
| L02AE01 | Buserelin |
| L02AE02 | Leuprorelin |
| L02AE03 | Goserelin |
| L02AE04 | Triptorelin |
| L02AE05 | Histrelin |
| L02BA01 | Tamoxifen |
| L02BA02 | Toremifene |
| L02BA03 | Fulvestrant |
| L02BB01 | Flutamide |
| L02BB02 | Nilutamide |
| L02BB03 | Bicalutamide |
| L02BB04 | Enzalutamide |
| L02BG01 | Aminogluthetimide |
| L02BG02 | Formestane |
| L02BG03 | Anastrozole |
| L02BG04 | Letrozole |
| L02BG05 | Vorozole |
| L02BG06 | Exemestane |
| L02BX01 | Abarelix |
| L02BX02 | Degarelix |
| L02BX03 | Abiraterone |
| L03AA02 | Filgrastim |
| L03AA03 | Molgramostim |
| L03AA09 | Sargramostim |
| L03AA10 | Lenograstim |
| L03AA12 | Ancestim |
| L03AA13 | Pegfilgrastim |
| L03AA14 | Lipegfilgrastim |
| L03AA15 | Balugrastim |
| L03AA16 | Empegfilgrastim |
| L03AB01 | Interferon alfa natural |
| L03AB02 | Interferon beta natural |
| L03AB03 | Interferon gamma |
| L03AB04 | Interferon alfa-2a |
| L03AB05 | Interferon alfa-2b |
| L03AB06 | Interferon alfa-n1 |
| L03AB07 | Interferon beta-1a |
| L03AB08 | Interferon beta-1b |
| L03AB09 | Interferon alfacon-1 |
| L03AB10 | Peginterferon alfa-2b |
| L03AB11 | Peginterferon alfa-2a |
| L03AB12 | Albinterferon alfa-2b |
| L03AB13 | Peginterferon beta-1a |
| L03AB14 | Cepeginterferon alfa-2b |
| L03AB60 | Peginterferon alfa-2b, combinations |
| L03AB61 | Peginterferon alfa-2a, combinations |
| L03AB90 | Interferone ricombinante omega di origine felina |
| L03AC01 | Aldesleukin |
| L03AC02 | Oprelvekin |
| L03AX01 | Lentinan |
| L03AX02 | Roquinimex |
| L03AX03 | BCG vaccine |
| L03AX04 | Pegademase |
| L03AX05 | Pidotimod |
| L03AX07 | Poly I:C |
| L03AX08 | Poly ICLC |
| L03AX09 | Thymopentin |
| L03AX10 | Immunocyanin |
| L03AX11 | Tasonermin |
| L03AX12 | Melanoma vaccine |
| L03AX13 | Glatiramer acetate |
| L03AX14 | Histamine dihydrochloride |
| L03AX15 | Mifamurtide |
| L03AX16 | Plerixafor |
| L03AX17 | Sipuleucel-T |
| L03AX18 | Cridanimod |
| L03AX19 | Dasiprotimut-T |
| L04AA02 | Muromonab-CD3 |
| L04AA03 | Antilymphocyte immunoglobulin (horse) |
| L04AA04 | Antithymocyte immunoglobulin (rabbit) |
| L04AA06 | Mycophenolic acid |
| L04AA10 | Sirolimus |
| L04AA13 | Leflunomide |
| L04AA15 | Alefacept |
| L04AA18 | Everolimus |
| L04AA19 | Gusperimus |
| L04AA21 | Efalizumab |
| L04AA22 | Abetimus |
| L04AA23 | Natalizumab |
| L04AA24 | Abatacept |
| L04AA25 | Eculizumab |
| L04AA26 | Belimumab |
| L04AA27 | Fingolimod |
| L04AA28 | Belatacept |
| L04AA29 | Tofacitinib |
| L04AA31 | Teriflunomide |
| L04AA32 | Apremilast |
| L04AA33 | Vedolizumab |
| L04AA34 | Alemtuzumab |
| L04AA35 | Begelomab |
| L04AA36 | Ocrelizumab |
| L04AA37 | Baricitinib |
| L04AB01 | Etanercept |
| L04AB02 | Infliximab |
| L04AB03 | Afelimomab |
| L04AB04 | Adalimumab |
| L04AB05 | Certolizumab pegol |
| L04AB06 | Golimumab |
| L04AC01 | Daclizumab |
| L04AC02 | Basiliximab |
| L04AC03 | Anakinra |
| L04AC04 | Rilonacept |
| L04AC05 | Ustekinumab |
| L04AC06 | Mepolizumab |
| L04AC07 | Tocilizumab |
| L04AC08 | Canakinumab |
| L04AC09 | Briakinumab |
| L04AC10 | Secukinumab |
| L04AC11 | Siltuximab |
| L04AC12 | Brodalumab |
| L04AC13 | Ixekizumab |
| L04AC14 | Sarilumab |
| L04AD01 | Ciclosporin |
| L04AD02 | Tacrolimus |
| L04AD03 | Voclosporin |
| L04AX01 | Azathioprine |
| L04AX02 | Thalidomide |
| L04AX03 | Methotrexate |
| L04AX04 | Lenalidomide |
| L04AX05 | Pirfenidone |
| L04AX06 | Pomalidomide |
Expansion from tx.fhir.org based on codesystem WHO ATC version 2025
This value set contains 223 concepts
Explanation of the columns that may appear on this page:
| Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies |
| System | The source of the definition of the code (when the value set draws in codes defined elsewhere) |
| Code | The code (used as the code in the resource instance) |
| Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application |
| Definition | An explanation of the meaning of the concept |
| Comments | Additional notes about how to use the code |
IG © 2022+ IDEA4RC Project. Package hl7.eu.fhir.idea4rc#0.1.0 based on FHIR 4.0.1. Generated 2026-01-19
Links: Table of Contents |
QA Report
The IDEA4RC project has received funding from the European Union's Horizon 2020
research and innovation programme under grant agreement No. 101057048.
